Manipulation of anabolic and catabolic responses with bone morphogenetic protein and zoledronic acid in a rat spinal fusion model

Bone

Volumn 58, Issue , 2014, Pages 26-32

  Kodera, Ryuzo ^a   Miyazaki, Masashi ^a   Yoshiiwa, Toyomi ^a   Kawano, Masanori ^a   Kaku, Nobuhiro ^a   Tsumura, Hiroshi ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Bone morphogenetic protein; Rat model; Spine fusion; Zoledronic acid

Indexed keywords

DRUG CARRIER; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; ZOLEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MASS; BONE TISSUE; CALLUS; CATABOLISM; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; EUTHANASIA; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HISTOLOGY; MALE; MICRO-COMPUTED TOMOGRAPHY; NONHUMAN; PALPATION; POSTOPERATIVE PERIOD; PROTEIN SYNTHESIS; RAT; SCORING SYSTEM; SINGLE DRUG DOSE; SPINE FUSION; SPINE RADIOGRAPHY; TRABECULAR BONE;

BONE MORPHOGENETIC PROTEIN; RAT MODEL; SPINE FUSION; ZOLEDRONIC ACID;

ANIMALS; BONE MORPHOGENETIC PROTEIN 2; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; HUMANS; IMAGING, THREE-DIMENSIONAL; IMIDAZOLES; MALE; OSTEOCLASTS; PALPATION; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; SPINAL FUSION; SPINE; TRANSFORMING GROWTH FACTOR BETA; X-RAY MICROTOMOGRAPHY;

EID: 84886258481     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2013.09.021     Document Type: Article

References (36)

1. Boden S.D. Overview of the biology of lumbar spine fusion and principles for selecting a bone graft substitute. Spine (Phila Pa 1976) 2002, 27:S26-S31.
2. Bridwell K.H., Sedgewick T.A., O'Brien M.F., Lenke L.G., Baldus C. The role of fusion and instrumentation in the treatment of degenerative spondylolisthesis with spinal stenosis. J Spinal Disord 1993, 6:461-472.
3. McGuire R.A., Amundson G.M. The use of primary internal fixation in spondylolisthesis. Spine (Phila Pa 1976) 1993, 18:1662-1672.
4. West J.L., Bradford D.S., Ogilvie J.W. Results of spinal arthrodesis with pedicle screw-plate fixation. J Bone Joint Surg Am 1991, 73:1179-1184.
5. Zdeblick T.A. A prospective, randomized study of lumbar fusion. Preliminary results. Spine (Phila Pa 1976) 1993, 18:983-991.
6. Kanatani M., Sugimoto T., Kaji H., Kobayashi T., Nishiyama K., Fukase M., et al. Stimulatory effect of bone morphogenetic protein-2 on osteoclast-like cell formation and bone-resorbing activity. J Bone Miner Res 1995, 10:1681-1690.
7. Okamoto M., Murai J., Yoshikawa H., Tsumaki N. Bone morphogenetic proteins in bone stimulate osteoclasts and osteoblasts during bone development. J Bone Miner Res 2006, 21:1022-1033.
8. Wozney J.M., Rosen V., Celeste A.J., Mitsock L.M., Whitters M.J., Kriz R.W., et al. Novel regulators of bone formation: molecular clones and activities. Science 1988, 242:1528-1534.
9. Boden S.D., Kang J., Sandhu H., Heller J.G. Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies. Spine (Phila Pa 1976) 2002, 27:2662-2673.
10. Suh D.Y., Boden S.D., Louis-Ugbo J., Mayr M., Murakami H., Kim H.S., et al. Delivery of recombinant human bone morphogenetic protein-2 using a compression-resistant matrix in posterolateral spine fusion in the rabbit and in the non-human primate. Spine (Phila Pa 1976) 2002, 27:353-360.
11. Kanayama M., Hashimoto T., Shigenobu K., Yamane S., Bauer T.W., Togawa D. A prospective randomized study of posterolateral lumbar fusion using osteogenic protein-1 (OP-1) versus local autograft with ceramic bone substitute: emphasis of surgical exploration and histologic assessment. Spine (Phila Pa 1976) 2006, 31:1067-1074.
12. Glassman S.D., Carreon L., Djurasovic M., Campbell M.J., Puno R.M., Johnson J.R., et al. Posterolateral lumbar spine fusion with INFUSE bone graft. Spine J 2007, 7:44-49.
13. Dimar J.R., Glassman S.D., Burkus K.J., Carreon L.Y. Clinical outcomes and fusion success at 2years of single-level instrumented posterolateral fusions with recombinant human bone morphogenetic protein-2/compression resistant matrix versus iliac crest bone graft. Spine (Phila Pa 1976) 2006, 31:2534-2539.
14. Louis-Ugbo J., Kim H.S., Boden S.D., Mayr M.T., Li R.C., Seeherman H., et al. Retention of 125I-labeled recombinant human bone morphogenetic protein-2 by biphasic calcium phosphate or a composite sponge in a rabbit posterolateral spine arthrodesis model. J Orthop Res 2002, 20:1050-1059.
15. Russell R.G.G. Bisphosphonates: the first 40years. Bone 2011, 49(1):2-19.
16. Rogers M.J., Crockett J.C., Coxon F.P., Mönkkönen J. Biochemical and molecular mechanisms of action of bisphosphonates. Bone 2011, 49(1):34-41.
17. Black D.M., Delmas P.D., Eastell R., Reid I.R., Boonen S., Cauley J.A., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356:1809-1822.
18. Hosking D., Lyles K., Brown J.P., Fraser W.D., Miller P., Curiel M.D., et al. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. J Bone Miner Res 2007, 22:142-148.
19. Ross J.R., Saunders Y., Edmonds P.M., Patel S., Broadley K.E., Johnston S.R. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ 2003, 327:469.
20. Bransford R., Goergens E., Briody J., Amanat N., Cree A., Little D. Effect of zoledronic acid in an L6-L7 rabbit spine fusion model. Eur Spine J 2007, 16:557-562.
21. Schimmer R.C., Bauss F. Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies. Clin Ther 2003, 25:19-34.
22. McClung M., Harris S.T., Miller P.D., Bauer D.C., Davison K.S., Dian L., et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med 2013, 126(1):13-20.
23. Doi Y., Miyazaki M., Yoshiiwa T., Hara K., Kataoka M., Tsumura H. Manipulation of the anabolic and catabolic responses with BMP-2 and zoledronic acid in a rat femoral fracture model. Bone 2011, 49:777-782.
24. Miyazaki M., Morishita Y., He W., Hu M., Sintuu C., Hymanson H.J., et al. A porcine collagen-derived matrix as a carrier for recombinant human bone morphogenetic protein-2 enhances spinal fusion in rats. Spine J 2009, 9:22-30.
25. Yamamoto M., Takahashi Y., Tabata Y. Controlled release by biodegradable hydrogels enhances the ectopic bone formation of bone morphogenetic protein. Biomaterials 2003, 24:4375-4383.
26. Amanat N., McDonald M., Godfrey C., Bilston L., Little D. Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair. J Bone Miner Res 2007, 22:867-876.
27. Lehman R.A., Kuklo T.R., Freedman B.A., Cowart J.R., Mense M.G., Riew K.D. The effect of alendronate sodium on spinal fusion: a rabbit model. Spine J 2004, 4:36-43.
28. Takahata M., Ito M., Abe Y., Abumi K., Minami A. The effect of anti-resorptive therapies on bone graft healing in an ovariectomized rat spinal arthrodesis model. Bone 2008, 43:1057-1066.
29. Little D.G., McDonald M., Bransford R., Godfrey C.B., Amanat N. Manipulation of the anabolic and catabolic responses with OP-1 and zoledronic acid in a rat critical defect model. J Bone Miner Res 2005, 20:2044-2052.
30. Little D.G., Smith N.C., Williams P.R., Briody J.N., Bilston L.E., Smith E.J., et al. Zoledronic acid prevents osteopenia and increases bone strength in a rabbit model of distraction osteogenesis. J Bone Miner Res 2003, 18:1300-1307.
31. McDonald M.M., Dulai S., Godfrey C., Amanat N., Sztynda T., Little D.G. Bolus or weekly zoledronic acid administration does not delay endochondral fracture repair but weekly dosing enhances delays in hard callus remodeling. Bone 2008, 43:653-662.
32. Matos M.A., Tannuri U., Guarniero R. The effect of zoledronate during bone healing. J Orthop Traumatol 2010, 11:7-12.
33. Laursen M., Hoy K., Hansen E.S., Gelineck J., Christensen F.B., Bunger C.E. Recombinant bone morphogenetic protein-7 as an intracorporal bone growth stimulator in unstable thoracolumbar burst fractures in humans: preliminary results. Eur Spine J 1999, 8:485-490.
34. McClellan J.W., Mulconrey D.S., Forbes R.J., Fullmer N. Vertebral bone resorption after transforaminal lumbar interbody fusion with bone morphogenetic protein (rhBMP-2). J Spinal Disord Tech 2006, 19:483-486.
35. Pradhan B.B., Bae H.W., Dawson E.G., Patel V.V., Delamarter R.B. Graft resorption with the use of bone morphogenetic protein: lessons from anterior lumbar interbody fusion using femoral ring allografts and recombinant human bone morphogenetic protein-2. Spine (Phila Pa 1976) 2006, 31:E277-E284.
36. Sheeherman H.J., Ki X., Blake C., Gavin D., Wozney J.M., Bouxsein M.L. Histologyindicates bisphosphonate limits transient resorption without decreasing subsequent bone induction in non human primate core defects treated with BMP-2/ACS. J Bone Miner Res 2001, 16(S1):S438.